# US 8,541,544 B2 · Molecular marker for cancer stem cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,544 B2
- Document ID: US8541544B2
- Status: Granted
- Kind: B2
- Application number: 13/126,039
- Filed: 2009-10-27
- Published: 2011-10-27
- Granted: 2013-09-24
- Earliest claimed: 2008-10-27
- Assignees: Dainippon Sumitomo Pharma Co., Ltd.; Sapporo Medical University
- Applicants: Toshihiko Torigoe; Yoshihiko Hirohashi; Noriyuki Satoh; Kenjiro Kamiguchi; Rena Morita; Satoshi Nishizawa; Akari Takahashi
- Inventors: Toshihiko Torigoe; Yoshihiko Hirohashi; Noriyuki Satoh; Kenjiro Kamiguchi; Rena Morita; Satoshi Nishizawa; Akari Takahashi
- Web page: https://patentgrep.com/patent/US8541544B2

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5017: {for testing neoplastic activity}
- G01N 33/575: for cancer
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

## Claims

### Claim 1

An isolated peptide which is 10 to 11 amino acids long, and is
(i) Or7c1 93: TYAGCLSQIF (SEQ ID NO: 75), or
(ii) Or7c1 93: TYAGCLSQIF (SEQ ID NO: 75) in which the second amino acid from N-terminal is substituted to tryptophan, phenylalanine or methionine and/or the C-terminal amino acid is substituted to leucine, isoleucine, tryptophan or methionine in the polypeptide;
wherein said isolated peptide has HLA-A24 binding ability,
wherein one amino acid is optionally added to an N-terminal end or C-terminal end of the peptide of (i) or (ii).

### Claim 2 (depends on 1)

A pharmaceutical composition that comprises at least one of the isolated peptides according to claim 1 as an active ingredient.

### Claim 3 (depends on 1)

An isolated peptide according to claim 1, wherein the isolated peptide is Or7c1 93: TYAGCLSQIF (SEQ ID NO: 75).

### Claim 4 (depends on 3)

A pharmaceutical composition that comprises at least one of the isolated peptides according to claim 3 as an active ingredient.

### Claim 5 (depends on 1)

A method for inducing CTL comprising a step of contacting a cell population comprising blood mononuclear cells with an isolated peptide according to claim 1.

### Claim 6 (depends on 3)

A method for inducing CTL comprising a step of contacting a cell population comprising blood mononuclear cells with an isolated peptide according to claim 3.